Board of Directors
The Board, working with senior management, is responsible for overall business performance. It approves company goals and directions, plans and performance and ensures appropriate policies, procedures and systems are in place. The Board Charter formalises and discloses the functions reserved to the board and those delegated to management.
Chairman Age 69
Appointed to the Board 1 March 2005: Chairman of the Nomination Committee. Member of the Audit and Risk and People & Culture Committees.
Background: Global executive and leadership experience in capital markets and derivatives, and a background in venture capital activities. Former President of NationsBank-CRT, Chicago and Managing Director of Hong Kong Bank Limited, London.
Other boards: Chairman, ASX Limited and Director, Servcorp Limited. Non-executive Chairman, QBiotics and member of the Macquarie University Faculty of Business and Economics Advisory Board.
Former directorships: Chairman, Snowy Hydro Limited and SFE Corporation Limited. Director, Servcorp Limited, St George Bank Limited, Exco Resources NL, DCA Group Limited and MIA Group Limited.
Qualifications: BA (Hons), FAICD, CA
CEO & President and Managing Director Age 52
Appointed to the Board 14 November 2017 and as CEO & President 3 January 2018: Member of the Medical Science and Technology & Innovation Committees.
Background: Joined Cochlear in 2000 and has a wealth of experience across the Company in roles including Chief Operating Officer, SVP, Manufacturing and Logistics and President, Asia Pacific. Prior to joining Cochlear, worked for Boral and Boston Consulting Group. Dig is a member of the Male Champions of Change STEM group. Appointed as President of Cochlear on 31 July 2017 and became CEO & President on 3 January 2018.
Qualifications:BE (Hons), MBA
Non-executive Director Age 55
Appointed to the Board 2 August 2010: Chairman of the Audit and Risk Committee. Member of the People & Culture, Nomination and Technology & Innovation Committees.
Background: Extensive career in investment banking with senior roles in strategic analysis and corporate advice. Former Vice President of Deutsche Bank AG.
Other boards: Director, Santos Limited, ASX Limited and National Portrait Gallery. Member of the George Institute for Global Health Board. Chairman, Advance (Global Australian Network), Member of Australian Government Takeovers Panel and Chair, Australian Federal Government Steering Group for Digital Technology Pilot.
Former directorships: Director, Insurance Australia Group Limited. National director of the Australian Institute of Company Directors. Member of The Salvation Army Advisory Board. Chair of Macquarie Specialised Asset Management. Director, ANZ Investment Bank and Associate Director, HSBC London.
Qualifications: BCom, FAICD
Non-executive Director Age 70
Appointed to the Board 1 February 2007: Member of the Audit and Risk, Medical Science, Technology & Innovation and Nomination Committees.
Background: Extensive experience in the life sciences industry. Former Managing Director of Memtec Limited and President Asia for Pall Corporation.
Other boards: Chairman, SpeeDx and Director, Vaxxas and QBiotics.
Former directorships: Executive Chairman, Universal Biosensors.
Qualifications: BSc (Hons), MBA, FAICD
Non-executive Director Age 66
Appointed to the Board 1 August 2005: Member of the Audit and Risk, Medical Science, Nomination and Technology & Innovation Committees.
Background: Executive experience in global general management of healthcare products and medical devices. Former worldwide President of Cordis Cardiology (a Johnson & Johnson company) and President of Baxter's Cardiovascular Group, Europe.
Other boards: Director, Mesoblast Limited, Fisher & Paykel Healthcare and NIB Holdings Ltd. Chairman of Endoluminal Sciences and Director Cordis Asset Management Pty Ltd.
Former directorships: Chairman, CardieX (formerly Atcor Medical).
Qualifications: BE Civil, MBA
Glen Boreham, AM
Non-executive Director Age 55
Appointed to the Board 1 January 2015: Chairman of the People & Culture Committee. Member of the Audit and Risk, Nomination and Technology & Innovation Committees.
Background: Led organisations in information technology, new media and the creative industries through periods of rapid change and innovation. Former Managing Director of IBM Australia and New Zealand.
Other boards: Director, Southern Cross Media Group and Link Group. Chairman, Advisory Board IXUP.
Former directorships: Director of Data#3. Chairman of Screen Australia, Advance (Global Australian Network), Business School and Industry Advisory Board for the University of Technology, Sydney.
Qualifications: BEc, FAICD
Non-executive Director Age 51
Appointed to the Board 1 January 2015: Chairman of the Technology & Innovation Committee. Member of the Audit and Risk, Nomination and People & Culture Committees.
Background: Extensive experience leading technology-enabled businesses across e-commerce, media and financial services. Former Chief Executive Officer of netus, Hoyts Cinemas, ecorp and eBay Australia and New Zealand.
Other boards: Director, Westpac Banking Corporation, Ramsay Health Care Limited and Deputy Group Pty Ltd. Senior Advisor to McKinsey & Company. Member of Investment Committee, CSIRO Innovation fund (Main Sequence Ventures) and Director of SCEGGS Darlinghurst Limited.
Former directorships: Director of Insurance Australia Group Limited, Social Ventures Australia and kikki.K Holdings Pty Ltd. Chairman of ninemsn, Allure Media and Downstream Media.
Qualifications: BA, MBA, GAICD
Prof Bruce Robinson, AC
Non-executive Director Age 62
Appointed to the Board 13 December 2016: Chairman of Medical Science Committee. Member of the Nomination, People & Culture and Technology & Innovation Committees.
Background: Over 20 years' leadership experience as an academic physician/scientist across research, healthcare and medicine, and tertiary education. Former Dean, The University of Sydney's Sydney Medical School, Head of Medicine at Sydney's Royal North Shore Hospital and Head of the Cancer Genetics Laboratory at the Kolling Institute for Medical Research.
Other boards: Chairman, National Health and Medical Research Council and Medical Benefits Schedule Review Taskforce. Director, MaynePharma, and QBiotics. Director, Woolcock Institute of Medical Research and Senior Advisor to McKinsey & Company.
Former directorships: Director of Firefly and Digital Health Agency CRC.
Qualifications: MD, MSc, FRACP, FAAHMS, FAICD
Non-executive Director Age 54
Appointed to the Board effective 1 December 2018: Member of the Nomination, Medical Science and Technology & Innovation Committees.
Background: Over 30 years' global experience in the pharmaceutical industry with significant experience in building relationships with professionals within the healthcare industry. Former Global President, Pharmaceuticals at GlaxoSmithKline.
Other boards: Director, CSL Limited and Immunocore Limited. Senior Advisor, CellResearch Corp and C-Bridge Group, Hikma PLC.
Qualifications: BSc (Hons)
Non-executive Director Age 63
Appointed to the Board 1 January 2020: Member of the Nomination, Medical Science and Technology & Innovation Committees.
Background: Over 40 years’ experience in the medical device industry with extensive executive leadership experience. Former Managing Director and CEO of Fisher & Paykel Healthcare Corporation Limited responsible for the global business and operations including the design, manufacture and marketing of innovative products and systems for use in respiratory care, acute care and the treatment of obstructive sleep apnea.
Other boards: Director, Fisher & Paykel Healthcare Corporation Ltd, Council member, The University of Auckland, Director, Tait International Limited, Chair, New Zealand Medical Technology Centre of Research Excellence, Director, Medical Research Commercialisation Fund.
Qualifications: BE (Hons), Electrical